MLM Share Price

Open 0.44 Change Price %
High 0.44 1 Day 0.00 0.00
Low 0.43 1 Week 0.00 0.00
Close 0.44 1 Month 0.02 4.76
Volume 2515060 1 Year 0.09 25.71
52 Week High 0.54
52 Week Low 0.31
MLM Important Levels
Resistance 2 0.45
Resistance 1 0.45
Pivot 0.44
Support 1 0.43
Support 2 0.43
BIT Italy Most Active Stocks
RN 0.04 0.00%
RN 0.04 0.00%
PMI 0.36 0.00%
PMI 0.36 0.00%
TIT 0.75 1.35%
ISP 2.89 0.00%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
More..
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
AE 0.50 8.70%
AE 0.50 8.70%
DIS 0.28 7.69%
DIS 0.28 7.69%
DIS 0.28 7.69%
DIS 0.28 7.69%
More..
BIT Italy Top Losers Stocks
ME 0.09 -10.00%
ME 0.09 -10.00%
FTL 3.65 -7.36%
TBS 1.64 -6.82%
STEF 0.19 -5.00%
POPR 0.59 -4.84%
BIM 0.65 -4.41%
BIM 0.65 -4.41%
ZUCR 0.24 -4.00%
S24 1.70 -3.95%
More..

Molmed (BIT: MLM)

MLM Technical Analysis 3
As on 1st Nov 2017 MLM Share Price closed @ 0.44 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.43 & Buy for SHORT-TERM with Stoploss of 0.42 we also expect STOCK to react on Following IMPORTANT LEVELS.
MLM Target for November
1st Target up-side 0.48
2nd Target up-side 0.51
3rd Target up-side 0.54
1st Target down-side 0.4
2nd Target down-side 0.37
3rd Target down-side 0.34
MLM Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.molmed.com
MLM Address
MLM
Via Olgettina, 58
Milan, MI 20132
Italy
Phone: 39 02 212771
Fax: 39 02 21 27 73 25
MLM Latest News
Interactive Technical Analysis Chart Molmed ( MLM BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Molmed
MLM Business Profile
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of therapies to treat cancer. Its products include TK, a cell therapy product, which is in Phase III clinical trials enabling safe transplant of haematopoietic stem cells from partially compatible haplo-identical donors for the treatment of haematological malignancies. The company’s products also comprise NGR-hTNF, a recombinant biological drug that is in Phase II clinical trials for various types of solid tumours, such as colorectal, hepatocellular carcinoma and mesothelioma, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as is in Phase III clinical trials in mesothelioma patients. It has an agreement with Telethon Foundation for the co-development and clinical-grade manufacture of gene therapies for rare genetic diseases; San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy; and GlaxoSmithKline for the development and production for clinical use of a viral vector for ADA, as well as a strategic partnership with Takara Bio, Inc. for TK cell therapy. The company was founded in 1996 and is based in Milan, Italy.